PubMed Health⌕ Search

Biomedical subjects

T Paparrigopoulos

Publications and source records attributed to T Paparrigopoulos.

8 recordsLinked to original sources
PubMed2003

Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration.

BACKGROUND: Social anxiety disorder is fairly prevalent among alcohol abusing/dependent subjects. The objective of the present study was to investigate: (a) the incidence of social anxiety symptoms in inpatient alcoholics, (b) the effect of alcohol detoxification on these symptoms, and (c) whether a combined psychotherapeutic/mirtazapine treatment during the post-detoxification phase of alcoholism has a greater impact on the aforementioned symptoms than a non-pharmacological approach. METHOD: Social anxiety symptoms were assessed through the Liebowitz Social Anxiety Scale (LSAS) following a 4-5-week detoxification period in two groups: group A (n=21) that followed a detoxification protocol of cognitive-behavioral orientation and group B (n=33) that was assigned to mirtazapine in addition to the standard protocol. Concomitant psychopathology was monitored through the HARS and HDRS, and level of functioning through the GAS. RESULTS: A marked reduction of social anxiety symptoms was evidenced in both groups. However, patients on mirtazapine improved significantly more compared to controls. LIMITATIONS: A single measure of social anxiety, i.e., the LSAS was used. Also, a longer follow-up period is needed to ascertain remission of social anxiety symptoms. CONCLUSIONS: The present study found a rather high incidence of social anxiety symptoms in inpatient alcoholics which subsided following alcohol detoxification; moreover, it provides preliminary evidence that a combined psychotherapeutic/mirtazapine treatment (30-60 mg/daily) has a greater impact on the aforementioned symptoms than non-pharmacological treatment alone.

Adrenergic alpha-Antagonists↗
PubMed2002

Impact of alcohol detoxification on anxiety and depressive symptoms.

Anxiety and depression are frequently encountered 'collateral' symptoms in alcohol abusing subjects. The present study investigated the effect of detoxification on these symptoms over 4-5 weeks of abstinence from alcohol. Psychopathology and global functioning were assessed at baseline and at weekly intervals over this period from 28 alcoholics treated on an inpatient basis. At intake, they displayed high levels of anxiety and depression; also, global functioning was seriously impaired. Following detoxification, scores on all measures of psychopathology were notably reduced. These findings allude to the depression-inducing properties of alcohol, which should be considered in the differential diagnosis of mood symptoms in alcohol abusing individuals.

Adult↗
PubMed2002

Melatonin response to atenolol administration in depression: indication of beta-adrenoceptor dysfunction in a subtype of depression.

OBJECTIVE: To investigate peripheral beta-adrenoceptor sensitivity in depression by assessing urinary melatonin pre- and post-administration of atenolol. METHOD: Overnight urinary melatonin pre- and post-administration of 100 mg oral atenolol was assessed in 36 depressed subjects and 47 controls. RESULTS: Baseline melatonin was significantly lower in depressed patients than controls (P=0.004). Melatonin following atenolol administration was strongly reduced in both groups (P < 0.0001). This reduction depends on whether the subject is a high or low (cutoff: 0.25 nmol/l) baseline melatonin excretor (P=0.025) and on whether he is depressed being a low excretor (P=0.048). A negative correlation (P=0.007) was found between melatonin decrease after atenolol and the Montgomery-Asberg Depression Rating Scale score. CONCLUSION: Atenolol strongly reduces melatonin in depressed and control subjects; this decrease relates inversely to the severity of depressive symptoms. Furthermore, responsiveness to atenolol differs between low melatonin depressed patients and low excretor controls, alluding to beta-adrenoceptor up-regulation in a subtype of depression.

Adrenergic beta-Antagonists↗
PubMed2001

Melatonin response to clonidine administration in depression: indication of presynaptic alpha2-adrenoceptor dysfunction.

BACKGROUND: The aim of this study was to investigate alpha2-adrenoceptor sensitivity in depression, by using melatonin response to clonidine administration as an index of alpha2-adrenoceptor functioning. METHOD: 35 depressed subjects and 41 healthy controls were assessed for overnight urinary melatonin pre- and post-administration of oral clonidine. RESULTS: Administration of clonidine significantly reduced melatonin concentrations in depressed patients but not in control subjects. LIMITATION: A single oral dose (0.15 mg) of clonidine was administered. CONCLUSIONS: Further indication is provided for presynaptic alpha2-adrenoceptor dysfunction in depression with the application of an alternative pharmacological challenge method.

Adult↗
PubMed2000

Sleep spindle incidence dynamics: a pilot study based on a Markovian analysis.

Results are reported, based on 5 healthy subjects, concerning patterns in the dynamics of the sequential arrangement of spindles in human stage 2 sleep. Specifically, the conditional probability of incidence of successive spindle lengths and successive inter-spindle intervals is investigated. The results show that successive spindle lengths may be statistically independent. However, their distribution (histogram) may be similar for two different stage 2 periods, one in the first third and another in the second third of the night sleep record. In contrast to the finding about spindle lengths, results show that successive inter-spindle intervals may not be statistically independent. Furthermore, the overall dynamics of the sequential arrangement of inter-spindle intervals may be similar for the two sleep periods. These findings are discussed in the context of the "sleep maintenance" role of spindles.

Adult↗
PubMed1999

Normative melatonin excretion: a multinational study.

The present study on overnight urinary melatonin was conducted on the most geographically dispersed population to date, over a 1 year period, also covering a broad age range (18-62 years). An inverse relationship between melatonin and age, as well as between melatonin and weight was observed for both genders. Females as a whole, had higher melatonin values than males. Furthermore, the excretion of melatonin exhibited a bimodal distribution, distinguishing two groups of individuals: low and high melatonin excretors. The cut-off point was set at 0.25 nmol/l for ages up to 40 years and at 0.20 nmol/l for subjects above this age. Since melatonin may be involved in several physiological and pathological processes, it could be of importance to detect the type of melatonin excretion that prevails in various conditions, using a simple noninvasive procedure such as the overnight urinary measurement. For that purpose, this large sample could serve as a worldwide reference databank across different ages and locations.

Adolescent↗
PubMedDate not supplied

Functional psychosis in middle-aged people presenting as a long-lasting confusion state: a report of two cases.

Two cases of functional psychosis in middle-aged people are reported. These patients manifested a long-lasting confusion, which eventually resolved. Attention is drawn to the fact that the clinical presentation of psychosis with predominant confusion symptoms is much more frequently encountered than usually believed. This particular clinical feature has been rather underestimated and only vaguely described in the current diagnostic classification systems. This often results in diagnostic perplexity in everyday psychiatric practice and delays the initiation of appropriate treatment. Finally, these reports are briefly discussed in the context of various proposed nosological entities, and the need for more systematic clinical information that would provide guidance on the classification of such psychotic disorders is suggested.

Bipolar Disorder↗